Pivotal Phase 3 Data for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast C

KENILWORTH, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the publication of results from the Phase 3 KEYNOTE-522 trial in the Feb. 10, 2022 edition of the New England Journal of Medicine. Results showed that neoadjuvant KEYTRUDA, Merck’s anti...

Related Keywords

United States ,Canada ,American ,Peter Dannenbaum ,Damini Chokshi ,Melissa Moody ,New England Journal ,Additional Data From ,Combined Positive Score ,Triple Negative Breast Cancer ,African American ,Neck Squamous Cell ,Bacillus Calmette Guerin ,Mismatch Repair Deficient ,Mismatch Repair Deficient Colorectal ,Important Safety Information ,Fatal Immune Mediated Adverse ,